Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors

Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors

Background: Waldenström macroglobulinemia (WM) is a rare subtype of B-cell lymphoma. Rituximab-based combination therapy and Bruton’s tyrosine kinase (BTK) inhibitors have greatly improved the prognosis of WM. Despite the high response rate and good tolerance of BTK inhibitors in treatment of WM, a...

Full description

Bibliographic Details
Main Authors: Jingjing Zhu, Xinyu Zhu, Fengyang Xie, Yi Ding, Huina Lu, Yan Dong, Ping Li, Jianfei Fu, Aibin Liang, Yu Zeng, Bing Xiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Pathology and Oncology Research
Subjects:
resistance
Waldenström macroglobulinemia
circulating tumor DNA (ctDNA)
BTK inhibitor
ascites
Online Access:https://www.por-journal.com/articles/10.3389/pore.2023.1611070/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2023.1611070/full

Similar Items